Protherics PLC
Rule 2.10 announcement
Not for release, publication or distribution (in whole or in part) in,
into or from any jurisdiction where to do so would constitute a
violation of the relevant laws of such jurisdiction.
London, UK; Brentwood, TN, US: 7 October 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, in accordance with Rule
2.10 of the City Code on Takeovers and Mergers (the "Code"),
confirms that as at the close of business on 6 October 2008, the
Company has 342,450,241 ordinary shares of 2 pence each in issue and
admitted to trading on the London Stock Exchange under the UK ISIN
Code GB0007029209.
/ Ends /
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Jefferies International Limited (Financial
Adviser) +44 (0) 20 7029 8292
Ian Crosbie, Director
+44 (0) 20 7776 1203
Nomura Code Securities Limited (Corporate Broker)
Phil Walker, Director
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno +1 212 850 5600
Or visit www.protherics.com
Dealing Disclosure Requirements
Under the provisions of Rule 8.3 of the Code, if any person is, or
becomes "interested" (directly or indirectly) in 1% or more of any
class of "relevant securities" of Protherics, all "dealings" in
any relevant securities" of Protherics (including by means of an option
in respect of, or a derivative references to, any such "relevant
securities") must be publicly disclosed by no later than 3.30pm (London
time) on the London business day following the date of the relevant
transaction. This requirement will continue until the date on which the
offer becomes, or is declared, unconditional as to acceptances, lapses
or is otherwise withdrawn or on which the "offer period" otherwise
ends. If two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire an "interest"
in"relevant securities" of Protherics they will be deemed to a single
person for the purpose of Rule 8.3.
Under the provisions of Rule 8.1 of the Code, all "dealings" in"relevant
securities" of Protherics by the potential offeror, or
by Protherics, or by any of their respective "associates", must be
disclosed by no later than 12.00 noon (London time) on the business day
following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose "relevant
securities""dealings" should be disclosed, and the number of such
securities in issue, can be found on the Takeover Panel's website at
www.takeoverpanel.org.uk.'Interests in securities' arise, in summary, when
a person has long
economic exposure, whether conditional or absolute, to changes in the
price of securities. In particular, a person will be treated as having
an 'interest' by virtue of the ownership or control of securities, or
by virtue of any option in respect of, or derivative referenced to,
securities.
Terms in quotation marks are defined in the Code, which can also be
found on the Panel's website. If you are in any doubt as to whether or
not you are required to disclose a 'dealing' under Rule 8, you should
consult the Panel.
This information is provided by RNS
The company news service from the London Stock Exchange
END
Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com